IP Library Granted Patent US 12,350,367
Granted Patent B2
US 12,350,367 · App. 17/020,731 · Granted Jul 8, 2025

Particles for administration of active ingredients and methods of making the same

Inventor: Ehsan Moaseri (Austin, TX)
Assignee: Nulixir Inc.
A61K9/10A23L29/10A23L29/30A23L33/155A61K9/0053A61K9/08A61K9/107A61K9/1075A61K9/1652A61K9/1664A61K9/167A61K9/4816A61K9/4833A61K9/4858A61K9/4866A61K9/4875A61K9/4891A61K9/5042A61K9/5089A61K9/513A61K9/5161A61K31/05A61K31/192A61K31/198A61K31/352A61K31/353A61K31/375A61K31/522A61K31/525A61K31/593A61K35/741A61K36/00A61K36/06A61K36/062A61K36/16A61K36/185A61K36/28A61K36/41A61K36/53A61K36/54A61K36/61A61K36/67A61K36/68A61K47/44A61K45/06B82Y5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,350,367
App. No.
17/020,731
Granted
Jul 8, 2025
Kind
B2
Abstract

Provided is a multilayer particle, the particle including: a core including: a first active ingredient; and a first polymer; a first shell, substantially surrounding the core, the first shell including: a second polymer; a second shell, substantially surrounding the first shell, the second shell including: a third polymer; and a plurality of emulsifying agents.

Claims (60)

1. A multilayer particle, the particle comprising:

a core comprising:

a first active ingredient, wherein the first active ingredient is caffeine; and

a first polymer, wherein the first polymer is sodium alginate;

a first shell, substantially surrounding the core, the first shell comprising:

a second active ingredient, wherein the second active ingredient is Bacopa;

a second polymer, wherein the second polymer is ethyl cellulose;

a second shell, substantially surrounding the first shell, the second shell comprising:

a third polymer, wherein the third polymer is shellac; and

an emulsifying agent, wherein the emulsifying agent is Polyglycerol polyricinoleate, wherein:

the particle has a Z-average diameter less than 1 micron.

2. The particle of claim 1 , wherein the core further comprises:

an ion exchange resin equilibrated with the first active ingredient.

3. The particle of claim 1 , wherein:

at least two of the first, the second, and the third polymers are hydrophobic.

4. The particle of claim 1 , wherein:

at least one of the second and the third polymers retards the release of the first active ingredient after consumption.

5. The particle of claim 1 , wherein:

the second shell is sprayed on the first shell with a centrifugal atomizer.

6. The particle of claim 1 , wherein:

the second shell is coated on the first shell with a fluidized bed.

7. The particle of claim 1 , wherein:

the second shell is formed using compression coating.

8. The particle of claim 1 , wherein:

the core has a diameter between 20% to 80% of the particle's diameter;

the first shell has a diameter between 5% to 20% of the particle's diameter; and

the second shell has a diameter between 5% to 20% of the particle's diameter.

9. The particle of claim 1 , wherein:

at least a portion of the emulsifying agents is in the core; and

at least a portion of the emulsifying agents is in the first shell.

10. The particle of claim 1 , wherein:

at least a portion of the emulsifying agents is in the core;

at least a portion of the emulsifying agents is in the first shell, and

at least a portion of the emulsifying agents is in the second shell.

11. The particle of claim 1 , wherein:

the particle is shelf stable for at least 12 months at room temperature.

12. The particle of claim 1 , wherein the first shell further comprises:

a wax selected from the group consisting of bees wax, carnauba wax, rice bran wax, camauba wax, candelilla wax, or combinations thereof.

13. A multilayer particle, the particle comprising:

a core comprising:

a first active ingredient, wherein the first active ingredient is selected from the group consisting of probiotics, caffeine, Echinacea purpurea, Echinacea angustifolia, Echinacea pallida, Acmella oleracea, Helichrysum umbraculigerum, Radula marginata , kava, black truffle, Syzygium aromaticum, Rosmarinus oficinalis , basil, oregano, lavender, true cinnamon, malabathrum, Cananga odorata , Riboflavin, Theanine, Ginkgo Biloba , Bacopa, and Rhodiola Rosea Extract, or combinations thereof; and

a first polymer, wherein the first polymer is selected from the group consisting of alginic acid, sodium alginate, potassium alginate, calcium alginate, agar, guar gum, xanthan gum, or combinations thereof;

a first shell, substantially surrounding the core, the first shell comprising:

a second active ingredient, wherein the second active ingredient is selected from the group consisting of probiotics, caffeine, hemp, cannabis, Echinacea purpurea, Echinacea angustifolia, Echinacea pallida, Acmella oleracea, Helichrysum umbraculigerum, Radula marginata , kava, black truffle, Syzygium aromaticum, Rosmarinus oficinalis , basil, oregano, lavender, true cinnamon, malabathrum, Cananga odorata , Riboflavin, Theanine, Ginkgo Biloba , Bacopa, and Rhodiola Rosea Extract, or combinations thereof;

a second polymer, wherein the second polymer is selected from the group consisting of shellac, methyl cellulose, hydroxy propyl cellulose, hydroxypropyl-methyl cellulose, ethyl methyl cellulose, carboxy methyl cellulose, ethyl cellulose, microcrystalline cellulose, cellulose, hypro mellose, hydroxyl propyl methyl cellulose, or combinations thereof;

a second shell, substantially surrounding the first shell, the second shell comprising:

a third polymer, wherein the third polymer is selected from the group consisting of shellac, methyl cellulose, hydroxy propyl cellulose, hydroxypropyl-methyl cellulose, ethyl methyl cellulose, carboxy methyl cellulose, ethyl cellulose, microcrystalline cellulose, cellulose, hypro mellose, hydroxyl propyl methyl cellulose, or combinations thereof; and

a plurality of emulsifying agents, wherein the plurality of emulsifying agents is selected from the group consisting of an extract of Quillaja, polysorbate 20, polysorbate 40, polysorbate 45, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 81 and polysorbate 85, polyglyceryl, gum acacia, Polyglycerol polyricinoleate, sorbitan oleate 85, sorbitan oleate 65, sorbitan oleate 83, sorbitan oleate 80, sorbitan oleate 60, sorbitan oleate 40, Xanthan gum, sorbitol, mannitol, glycerol, sodium alginate, or combinations thereof, wherein:

the particle has a Z-average diameter less than 1 micron.

14. A multilayer particle, the particle comprising:

a core comprising:

a first active ingredient, wherein the first active ingredient is caffeine; and

a first polymer, wherein the first polymer is sodium alginate;

a first shell, substantially surrounding the core, the first shell comprising:

a second active ingredient, wherein the second active ingredient is Bacopa;

a second polymer, wherein the second polymer is ethyl cellulose;

a second shell, substantially surrounding the first shell, the second shell comprising:

a third polymer, wherein the third polymer is shellac; and

an emulsifying agent, wherein the emulsifying agent is Polyglycerol polyricinoleate, wherein:

the particle has a Z-average diameter 0.5 to 5 microns.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2023
From: MOASERI, EHSAN
To: NULIXIR INC.
Reel/Frame 064523/0798 →
Continuity (5)
Provisional Application 63012058 · Apr 17, 2020
Provisional Application 62968591 · Jan 31, 2020
Provisional Application 62944912 · Dec 6, 2019
Provisional Application 62899595 · Sep 12, 2019
Related Publication 20210275461A1 · Sep 9, 2021
References Cited (120)
US 5827531A · Morrison · 1998 [cited by applicant]
US 6423363B1 · Traska et al. · 2002 [cited by applicant]
US 6720007B2 · Walt et al. · 2004 [cited by applicant]
US 7338924B2 · Varadaraj · 2008 [cited by applicant]
US 9155707B2 · Ying · 2015 [cited by examiner]
US 9427007B2 · Mason et al. · 2016 [cited by applicant]
US 10028919B2 · Kaufman · 2018 [cited by applicant]
US 10738268B2 · Leo · 2020 [cited by applicant]
US 11497809B2 · Wu et al. · 2022 [cited by applicant]
US 20020077372A1 · Gers-Barlag · 2002 [cited by applicant]
US 20030232083A1 · Wynn et al. · 2003 [cited by applicant]
US 20040014821A1 · Varadaraj · 2004 [cited by applicant]
US 20040192760A1 · Whittle et al. · 2004 [cited by applicant]
US 20050220996A1 · Berger · 2005 [cited by examiner]
US 20080226772A1 · Condeca Brinca et al. · 2008 [cited by applicant]
US 20100055246A1 · Ahn · 2010 [cited by applicant]
US 20100068290A1 · Ziegler et al. · 2010 [cited by applicant]
US 20100226995A1 · DeBrouse · 2010 [cited by applicant]
US 20100273895A1 · Stinchcomb et al. · 2010 [cited by applicant]
US 20100330189A1 · Niichel · 2010 [cited by applicant]
US 20110081451A1 · Siegel · 2011 [cited by examiner]
US 20110111020A1 · Yan et al. · 2011 [cited by applicant]
US 20110182998A1 · Reb et al. · 2011 [cited by applicant]
US 20110195157A1 · Niichel · 2011 [cited by applicant]
US 20110189298A1 · Vos et al. · 2011 [cited by applicant]
US 20120003288A1 · Mori · 2012 [cited by applicant]
US 20120177730A1 · Baron · 2012 [cited by applicant]
US 20130064759A1 · Mason et al. · 2013 [cited by applicant]
US 20140037744A1 · Buisson et al. · 2014 [cited by applicant]
US 20140242055A1 · Bromley · 2014 [cited by applicant]
US 20150150822A1 · Perumal et al. · 2015 [cited by applicant]
US 20150158004A1 · Meiners · 2015 [cited by examiner]
US 20150209298A1 · Haksar et al. · 2015 [cited by applicant]
US 20160008237A1 · Goldstein et al. · 2016 [cited by applicant]
US 20160128943A1 · Vepuri · 2016 [cited by examiner]
US 20160151328A1 · Doane et al. · 2016 [cited by applicant]
US 20160199378A1 · Niichel · 2016 [cited by applicant]
US 20170105946A1 · Stepovich · 2017 [cited by applicant]
US 20170157049A1 · Dandl et al. · 2017 [cited by applicant]
US 20170250063A1 · Chiu et al. · 2017 [cited by applicant]
US 20170281558A1 · Castan et al. · 2017 [cited by applicant]
US 20170367984A1 · Sagalowicz et al. · 2017 [cited by applicant]
US 20180071695A1 · Weitz et al. · 2018 [cited by applicant]
US 20180264059A1 · Speier · 2018 [cited by applicant]
US 20180325861A1 · Domb et al. · 2018 [cited by applicant]
US 20180344686A1 · Kleidon et al. · 2018 [cited by applicant]
US 20180360704A1 · Riefler et al. · 2018 [cited by applicant]
US 20180369177A1 · Fayad · 2018 [cited by applicant]
US 20190209633A1 · Speier · 2019 [cited by applicant]
US 20190240148A1 · Rodger et al. · 2019 [cited by applicant]
US 20190254302A1 · Abbaspourrad et al. · 2019 [cited by applicant]
US 20190298683A1 · Friedman · 2019 [cited by applicant]
US 20190321299A1 · Li · 2019 [cited by applicant]
US 20200009067A1 · Hoffman et al. · 2020 [cited by applicant]
US 20200101041A1 · Kleidon · 2020 [cited by applicant]
US 20200138736A1 · Merritt · 2020 [cited by applicant]
US 20210169816A1 · Moaseri · 2021 [cited by applicant]
US 20230157964A1 · Kvitnitsky et al. · 2023 [cited by applicant]
CA 2266518A1 · 1998 [cited by applicant]
CN 101001882A · 2007 [cited by applicant]
CN 101252845A · 2008 [cited by applicant]
CN 104473161A · 2015 [cited by applicant]
CN 104684540A · 2015 [cited by applicant]
CN 104812777A · 2015 [cited by applicant]
CN 105030716A · 2015 [cited by examiner]
CN 105146540A · 2015 [cited by applicant]
CN 107362154A · 2017 [cited by applicant]
EP 2201937A1 · 2010 [cited by applicant]
RU 2634904C1 · 2017 [cited by applicant]
WO WO2014151364A1 · 2014 [cited by examiner]
WO 2018183115A1 · 2018 [cited by applicant]
WO 2019071213A1 · 2019 [cited by applicant]
English translation CN 105030716 A (Year: 2024). [cited by examiner]
U.S. Appl. No. 17/020,693, filed Sep. 14, 2020. [cited by applicant]
U.S. Appl. No. 17/020,697, filed Sep. 14, 2020. [cited by applicant]
U.S. Appl. No. 17/020,692, filed Sep. 14, 2020. [cited by applicant]
U.S. Appl. No. 17/020,698, filed Sep. 14, 2020. [cited by applicant]
U.S. Appl. No. 17/020,729, filed Sep. 14, 2020. [cited by applicant]
U.S. Appl. No. 17/020,687, filed Sep. 14, 2020. [cited by applicant]
U.S. Appl. No. 17/020,690, filed Sep. 14, 2020. [cited by applicant]
International Application PCT/US2020/050772 filed Sep. 14, 2020. [cited by applicant]
Notice of Allowance in related U.S. Appl. No. 17/162,916 dated Jul. 20, 2022, 1-8 pages. [cited by applicant]
International Search Report and Written Opinion in related international application No. PCT/US2020/050772 dated Mar. 17, 2021. [cited by applicant]
Mushiolik, Gerald et al., “Double emulsions relevant to food systems: preparation, stability, and applications”, Comprehensive Reviews in Food Science and Food Safety, 2017, vol. 16, pp. 532-555. [cited by applicant]
Non-Final Office Action in related U.S. Appl. No. 17/020,697 dated Dec. 3, 2020. [cited by applicant]
Notice of Allowance in related U.S. Appl. No. 17/020,693 dated Jan. 26, 2021. [cited by applicant]
Final Office Action in related U.S. Appl. No. 17/020,697 dated Feb. 1, 2021. [cited by applicant]
Choi et al. Characterization of Capsaicin-Loaded Nanoemulsions Stabilized with Alginate and Chitosan by Self-assembly. Food Bioprocess Technol (2011) 4:1119-1126. (Year: 2011). [cited by applicant]
Leister et al. Evaluating the Stability of Double Emulsions—A Review of the Measurement Techniques for the Systematic Investigation of Instability Mechanisms. Colloids Interfaces 2020, 4, 8, 18 pages (review). (Year: 20… [cited by applicant]
Jacobs et al. Phase transitions in biological systems with many components. Biophysical Journal (2017) 112:683-691, (Year: 2017). [cited by applicant]
Madaan et al. Emulsion Technology and Recent Trends in Emulsion Applications. Int. Res. J. Pharm. 2014, 5(7): 533-542 (review). (Year: 2014). [cited by applicant]
Yang et al. Encapsulating plant ingredients for dermocosmetic application: an updated review of delivery systems and characterization techniques. International Journal of Cosmetic Science, 2020, 42, 16-28 (review). (Yea… [cited by applicant]
Corrected Notice of Allowability in related U.S. Appl. No. 17/20,693 dated Feb. 11, 2021. [cited by applicant]
Notice of Allowance in related U.S. Appl. No. 17/020,697 dated Aug. 17, 2021. [cited by applicant]
Extended Search Report for related European Patent Application 20862499.9, 15 pages. [cited by applicant]
Final Office Action for related U.S. Appl. No. 17/70994, issued Aug. 10, 2023, 15 pages. [cited by applicant]
Office Action for related Canadian Patent Application 315979, issued Nov. 10, 2023, 3 pages. [cited by applicant]
Non-Final Office Action for related U.S. Appl. No. 17/020,692, issued Nov. 20, 2023, 65 pages. [cited by applicant]
Final Office Action for related U.S. Appl. No. 17/854,297 issued on Jan. 11, 2024, 36 pages. [cited by applicant]
Notice of Allowance in related U.S. Appl. No. 17/020,729 dated Mar. 18, 2022, pp. 1-11. [cited by applicant]
International Preliminary Report on Patentability in related international application PCT/US2020/050772, pp. 1-5. [cited by applicant]
Jager-Lezer et al., “A Topical W/O/W Multiple Emulsion Containing Several Active Substances: Formulation, Characterization and Study of Release,” 26 J Control. Rel. 129, 1993, pp. 1-13. [cited by applicant]
Doucet et al., O/W emulsion and W/O/W multiple emulsion: physical characterization and skin pharmacokinetic comparison in the delivery process of caffeine., International Journal of Cosmetic Science, 1998, pp. 283-295. [cited by applicant]
Anton et al., “Aqueous-Core Lipid Nanocapsules for Encapsulating Fragile Hydrophilic and/or Lipophilic Molecules,” Langmuir Article, 25 (19) Jul. 16, 2009, pp. 11413-11419. [cited by applicant]
Raynal et al., “A topical W/O/W multiple emulsion containing several active substances: formulation, characterization and study of release.,” Journal of Controlled Release, 26, 1993 Elsevier Science Publishers B.V., pp.… [cited by applicant]
Moaseri, Ehsan, “Long-Term Colloidal Stability of Polymer-Grafted Silica Nanoparticles in Concentrated Brine at Elevated Temperatures,” Thesis, The University of Texas at Austin, May 2017, pp. 1-65. [cited by applicant]
Nanovex Biotechnologies, “How to Choose the Appropriate Nanovesicle,” https://www.nanovexbiotech.com/choose-appropriate-nanovesicle/, Mar. 15, 2017, pp. 1-6. [cited by applicant]
Guar et al., Nanovesicles of nitrendipine with lipid complex for transdermal delivery: pharmacokinetic and pharmacodynamic studies, Artificial Cells, Nanomedicine, and Biotechnology, https://www.tandfonline.com/doi/full… [cited by applicant]
Non-Final Office Action in related U.S. Appl. No. 17/162,916 dated Jun. 10, 2022, pp. 1-16. [cited by applicant]
Non-Final Office Action for related U.S. Appl. No. 17/020,690 issued Apr. 11, 2023, 91 pages. [cited by applicant]
Non-Final Office Action for related U.S. Appl. No. 17/854,297 issued Apr. 11, 2023, 32 pages. [cited by applicant]
Non-Final Office Action for related U.S. Appl. No. 17/470,994 issued May 3, 2024, 23 pages. [cited by applicant]
Office Action for related New Zealand Patent Application 809157 issued on May 7, 2024, 4 pages. [cited by applicant]
Office Action for related Canadian Patent Application 3150979 issued on May 17, 2024, 3 pages. [cited by applicant]
European Office Action for application no. 20862499.9 dated Aug. 13, 2024, pp. 1-5. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/854,297 dated Oct. 30, 2024. pp. 1-32. [cited by applicant]
Non-Final Office Action for related U.S. Appl. No. 17/470,994 issued Nov. 22, 2022, pp. 1 to 25. [cited by applicant]
Examination Report for related Chinese Patent Application 202080071670.6 issued on Jan. 28, 2023, 12 pages with English Translation on pp. 1 to 5. [cited by applicant]
Final Office Action for related U.S. Appl. No. 17/470,994 issued Feb. 11, 2025, 19 pages. [cited by applicant]
Non-Final Office Action for related U.S. Appl. No. 17/020,692 issued Mar. 6, 2025, 19 pages. [cited by applicant]